1. Introduction {#sec1}
===============

Particulate matter (PM) is a global environmental issue \[[@B1]\]. Recently, PM is increasing every year in China and in neighboring countries \[[@B2]\]. Particularly in Korea, outdoor activities are increasingly difficult and quality of life is diminishing from PM \[[@B3]\]. The higher the PM levels, the more people complain of various respiratory symptoms, and even those who do not have respiratory diseases need medical treatment reducing respiratory symptoms \[[@B4]\].

Generally, PM is known to cause abnormal inflammatory and coagulation responses in the entire body \[[@B5], [@B6]\]. And, PM can act as a direct irritant to the airway and causes respiratory disease. Incidences of airway disease and the frequency of acute exacerbations of asthma or chronic obstructive pulmonary disease (COPD) are increasing \[[@B7]\]. In addition, incidences of lung cancer are also expected to increase \[[@B8]\]. However, it is not fully understood how the airway reacts when inhaling PM. In addition, there is a lack of research on the adverse effects of PM in healthy people without respiratory disease.

Among the known respiratory tests, fractional exhaled nitric oxide (FeNO) is one that is a marker of airway inflammation \[[@B9]\]. FeNO is useful because it is noninvasive and can be easily examined in an outpatient clinic. When treating asthma and COPD, FeNO can predict airway inflammation and is also used to predict inhaled corticosteroid (ICS) responses \[[@B10]\]. Therefore, we investigated the correlation between PM and FeNO to determine whether PM causes airway inflammation.

2. Materials and Methods {#sec2}
========================

2.1. Data Collection {#sec2.1}
--------------------

We obtained FeNO results from January 2016 to December 2017 at the Korea University Guro Hospital by searching the hospital\'s electronic records. FeNO was measured using the nitric oxide delivery system monitor approved by the US Food and Drug Administration (NIOX MINO, Aerocrine, Sweden). We asked subjects about drugs used which could affect FeNO result at the time of the test. We instruct subjects to avoid exercise, smoking, and caffeine ingestion within 1 hour of FeNO test. This study was approved by the Institutional Review Board of the Korea University Guro Hospital (approval number: K2018-0377-001). Since our study was retrospective, patient consent was not necessary, and we maintained patient confidentiality.

We collected and analyzed the following medical records: age, gender, history of respiratory disease, pulmonary related treatment before the outpatient clinic visit, and the pulmonary function test (PFT).

We used particulate matter with a diameter of less than 10 *μ*m (PM~10~) as the representative value. PM~10~ data were provided by the government of the Republic of South Korea. PM~10~ data were obtained from a government measuring station located 800 meters from the Korea University Guro Hospital. And humidity and temperature data were also provided by the government of the Republic of South Korea.

2.2. Subjects {#sec2.2}
-------------

We included patients who visited our outpatient clinic for the first time and those who visited periodically due to asthma, allergic rhinitis, and COPD. Asthma was diagnosed based on the Global Initiative for Asthma (GINA) guidelines (patients showed positive for the bronchodilator reversibility test, positive for the bronchial challenge test, or positive for the exercise challenge test) \[[@B11]\]. Allergic rhinitis was diagnosed based on the Allergic Rhinitis and its Impact on Asthma (ARIA) guideline (patients had a typical history of allergic symptoms, such as rhinorrhea, sneezing, sneezing, nasal obstruction, and pruritus and diagnostic tests such as allergen-specific immunoglobulin E in the skin or blood specific immunoglobulin E) \[[@B12]\]. COPD was diagnosed based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines (PFT showed an obstructive pattern with a ratio of forced expiratory volume in the first second (FEV1) to forced vital capacity (FVC) of less than 70% in post bronchodilator spirometry) \[[@B13]\].

Patients were excluded if they (1) had a comorbidity that could limit daily life, such as cancer, myocardial infarction, brain hemorrhage, and brain infarction, (2) were chronically taking oral steroids or immunosuppressive drugs because of rheumatology disease or organ transplants, (3) were taking antibiotics due to an acute infection, (4) if they did not do PFT, or (5) if FeNO was performed during hospitalization.

2.3. Statistical Analysis {#sec2.3}
-------------------------

Data were analyzed using SPSS 20 software (SPSS for Windows, IBM Corporation, Armonk, NY, USA). Data were presented as average ± standard deviation (SD). The correlation coefficients between FeNO and PM~10~ were analyzed by a Pearson correlation analysis. To identify the most correlated times, we analyzed the correlation between FeNO and PM~10~ daily averages from the day of visit to 4 days before visit. All FeNO tests were performed on the day of the outpatient visit. In addition, we performed a multivariate linear regression analysis that included various factors affecting FeNO. We adjusted patient age, sex, history of respiratory disease, pulmonary related treatments before the visit, humidity, and temperature in a multivariate analysis. In the multivariate analysis, *B* was the regression coefficient, and the positive sign of the regression coefficient meant that the variables were positively associated. The trend lines were obtained by a linear model, using the equation *Y* = *b*0 + (*b*1 × *t*). "*b*1" is a slope of the regression line, and "*b*0" is an intercept of the regression line with the *Y*-axis. An additional sub-analysis was conducted by dividing the group according to history of respiratory disease and pulmonary related treatment. In our sub-analysis, "no history of respiratory disease" was defined as the group without asthma, COPD, allergic rhinitis, and no obstructive or restrictive pattern on the PFT. And, "no pulmonary medication" was defined as the group that did not use any medication or inhaler. *Pvalues* less than 0.05 were defined as statistically significant.

3. Results and Discussion {#sec3}
=========================

3.1. Baseline Characteristic {#sec3.1}
----------------------------

According to the exclusion criteria, 1,574 FeNO results and 1,439 patients were included ([Table 1](#tab1){ref-type="table"}). The average age was 48.3 ± 16.1 years. Men were 43.7 percent and women 56.3 percent of the patients. The asthma patients were 23.3 percent, the allergic rhinitis patients were 15.4 percent, and the COPD patients were 3.0 percent. 19.3 percent of events were using one or more pulmonary-related medications. 70.5 percent of events showed normal PFT findings. And the average value of PM10 was 47.3 ± 25.2 *μ*g/m^3^, and the average value of FeNO was 31.9 ± 30.8 ppb.

3.2. Correlation between PM~10~ and FeNO {#sec3.2}
----------------------------------------

In the Pearson correlation, FeNO positively correlated with PM~10~ at the day of the hospital visit (Pearson correlation coefficient = 0.061; *P* value = 0.016). And, FeNO also positively correlated with PM~10~ at two days before hospital visit (Pearson correlation coefficient = 0.057; *P* value = 0.023) ([Figure 1(a)](#fig1){ref-type="fig"}). There were no statistically significant correlations with other days. In the multivariate linear regression analysis, there was a positive correlation between FeNO and PM~10~, which was measured two days before the hospital visit (*B* = 0.051, *P* value = 0.026). If the PM~10~ increased by 100 *μ*g/m^3^, the FeNO value was expected to rise to 5.1 ppb. And, there was no statistically significant correlation with other days, including PM~10~ at the day of hospital visit ([Table 2](#tab2){ref-type="table"}).

3.3. Subgroup Analysis {#sec3.3}
----------------------

We performed the subgroup analysis according to the patient\'s history of respiratory disease and the pulmonary-related medication before the visit. And, the PM~10~ value two days before the hospital visit was used as the reference value because it was statistically significant in the multivariate analysis. PM~10~ results were similar among the subgroups. FeNO values were highest in the asthma group and lowest in the "no history of respiratory disease" group. In the Pearson correlation, the asthma group (Pearson correlation coefficient = 0.104; *P* value = 0.047), the "no history of respiratory disease" group (Pearson correlation coefficient = 0.081; *P* value = 0.030) and the "no pulmonary medication" group (Pearson correlation coefficient = 0.070; *P* value = 0.012) showed a positive correlation with FeNO (Figures [1(b)](#fig1){ref-type="fig"}--[1(d)](#fig1){ref-type="fig"}). In the multivariate linear regression analysis, there was a positive correlation between FeNO and PM~10~ in the "no history of respiratory disease" group (*B* = 0.083, *P* value = 0.024) and the "no pulmonary medication" group (*B* = 0.053, *P* value = 0.035). And, there was no statistically significant correlation with the other groups, including the asthma group ([Table 3](#tab3){ref-type="table"}).

4. Discussion {#sec4}
=============

This study is the first to demonstrate the correlation between PM~10~ and FeNO in Korea. A total of 1,574 events were included, and various factors that could affect FeNO were investigated. In addition to a univariate analysis, we performed a multivariate analysis to adjust various factors that could affect FeNO. Through the subgroup analysis, we confirmed the same results under various conditions. As such, we confirmed a positive correlation between PM~10~ and FeNO.

PM is generated from automobile exhaust and from construction and various industries, and it is a complex containing heavy metals and toxic chemicals. It is generally known that PM is composed of sulfate, nitrate, carbon, and black dust. PM~10~ means a PM with a diameter of less than 10 *μ*m, which is about one-fifth of that of human hair. PM stays in the atmosphere and is absorbed into the body through the skin, eyes, and the part of the respiratory tract exposed to the outside \[[@B14], [@B15]\]. PM can act as an irritant or allergen at the primary contact site and causes local adverse effects. In addition, PM causes abnormal inflammation and anticoagulation in the body \[[@B16], [@B17]\]. The airway, which is the primary exposed organ, is considered to have higher adverse effects from PM than other organs \[[@B18]\]. Even in healthy people, exposure to PM can lead to abnormal inflammatory responses in the airways.

PM is associated with the development and aggravation of respiratory diseases, such as asthma and COPD. In addition to the respiratory system, PM can cause disease in all organs of the body, including myocardial infarction, brain stroke, atopic dermatitis, and allergic rhinitis. On high PM days, healthy people also complain of nonspecific symptoms, such as runny nose, sputum, cough, and itching. Most of the PM-related studies so far have primarily focused on patients, but studies are also needed to analyze its effects on healthy people.

Nitric oxide (NO) is a biological mediator produced in human lungs \[[@B19]\]. The NO produced in the lungs is released outside during exhalation \[[@B20], [@B21]\]. NO is known to act as a vasodilator, bronchodilator, neurotransmitter, and inflammatory mediator in the airway \[[@B22]--[@B24]\]. Recently, NO was recognized as an important key to understanding lung biology and the pathophysiology of airway diseases. When inflammation occurs in the airway, nitric oxide synthase is upregulated and NO is generated in airway epithelial cells \[[@B25], [@B26]\]. The FeNO test has been increasingly used because it can easily and noninvasively measure NO. FeNO is also known to be associated with various interleukins, cytokines, and sputum eosinophilia \[[@B27], [@B28]\]. Therefore, FeNO is considered a test reflecting airway inflammation and airway hyperresponsiveness \[[@B29]--[@B31]\].

FeNO has a broad clinical use. The National Institute for Health and Care Excellence (NICE) guideline says that FeNO can be used for asthma diagnosis \[[@B32]\]. Other researches recommend that FeNO is useful as a reference for diagnosing asthma \[[@B33]\]. In particular, FeNO is more useful for young children who have difficulty performing PFT \[[@B34]\]. Some studies suggest that FeNO is also useful for screening high-risk groups for asthma \[[@B35]\]. FeNO is also useful for predicting ICS response \[[@B36]\]. Currently, medication control is symptom dependent for the treatment of asthma. FeNO can be used as an objective indicator for medication control \[[@B37]\].

Few studies have focused on the correlation between FeNO and PM \[[@B38]\]. Most of the previous studies were small cases or were limited to children \[[@B39]\]. In addition, most of the studies were conducted on asthma patients \[[@B40]\]. Our study was the first to include a large number of patients and healthy people.

Our research had some limitations. First, we did not adjust the height, weight, smoking history, nitric oxide, diet, house air quality, seasonality, and weather conditions in the multivariate analysis. FeNO is affected by various factors, for example, drugs, history of respiratory disease, gender, age, height, weight, smoking history, and nitric oxide level in atmosphere. Data on height, weight, and smoking history were not accurate and could not be analyzed. But, regarding seasonality and weather conditions, we included humidity and temperature. Secondly, the degree of exposure of PM may be slightly different. The degree of exposure may vary depending on the level of activity and location. To compensate for this, we excluded inpatients. Also, we excluded patients with diseases in which physical activity could be limited. Third, the differences in medication dosages and compliance were not corrected. In cases of patients with antihistamines, ICS, and intranasal corticosteroids, there were those with differences in the components and dosages of the drugs. There may also be differences in the proficiency and compliance with the inhaler. Fourth, we did not have big data from repeated comparisons of the same person. If repeated tests were to be conducted on the same person, a more stringent comparison would be possible. In our study, 115 subjects were repeatedly examined. A positive correlation was also observed in the repeated test group. Fifth, our study design and statistical analysis are very simple, so there are a lot of confounding variables. To overcome this limitation, we included a large number of subjects. In addition, many factors were included in the meta-analysis.

5. Conclusions {#sec5}
==============

We confirmed a positive correlation between PM~10~ and FeNO. Therefore, PM~10~ may cause airway inflammation. The same results were obtained in healthy persons as well as patients with respiratory conditions. Even healthy people may develop airway inflammation and respiratory symptoms caused by PM~10~. In addition, it should be considered that PM~10~ affects the FeNO value on days with very high PM~10~ value.
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###### 

Baseline characteristics.

                                                  Events
  ----------------------------------------------- -------------
  No. of outpatient clinic visits/patients        1,574/1,439
  Age (years)^*∗*^                                48.3 ± 16.1
  Gender                                           
   Male^†^                                        688 (43.7%)
   Female^†^                                      886 (56.3%)
  History of respiratory disease                   
   Asthma^†^                                      367 (23.3%)
   Chronic obstructive pulmonary disease^†^       48 (3.0%)
   Allergic rhinitis^†^                           242 (15.4%)
  Pulmonary-related medication before the visit    
   INS^†^                                         82 (5.2%)
   ICS^†^                                         204 (13.0%)
   LABA or LAMA^†^                                201 (12.8%)
   LTRA^†^                                        153 (9.7%)
   Antihistamine^†^                               187 (11.9%)
  Base-line spirometry after bronchodilation       
   FEV1 (liters)^*∗*^                             2.8 ± 0.8
   FEV1 (% of predicted value)^*∗*^               87.5 ± 14.6
   FVC (liters)^*∗*^                              3.5 ± 1.0
   FVC (% of predicted value)^*∗*^                90.1 ± 12.9
   Ratio of FEV1 to FVC (%)^*∗*^                  77.9 ± 10.1
   Bronchodilator response (positive)^†^          273 (17.3%)
   Asthma provocation test (positive)^†^          105 (6.7%)

INS, intranasal corticosteroids; ICS, inhaled corticosteroid; LABA, long-acting B agonist bronchodilator; LAMA, long-acting antimuscarinic agent bronchodilator; LTRA, leukotriene receptor antagonist; FEV1, forced expiratory volume in one second; FVC, forced vital capacity. ^*∗*^Numbers are presented as average ± standard deviation. ^†^Numbers are presented as *n* (%).

###### 

Correlation analysis of PM~10~ and FeNO by the Pearson correlation and multivariate linear regression analysis (most correlated time).

  PM~10~ measurement date            PM~10~ day average^*∗*^   Univariate   Multivariate           
  ---------------------------------- ------------------------- ------------ -------------- ------- -------
  The day of hospital visit          45.88 ± 20.24             0.061        0.016          0.043   0.064
  One day before hospital visit      45.74 ± 21.22             0.046        0.067          0.034   0.145
  Two days before hospital visit     47.33 ± 25.20             0.057        0.023          0.051   0.026
  Three days before hospital visit   47.68 ± 25.06             0.049        0.053          0.040   0.083
  Four days before hospital visit    47.88 ± 23.34             0.025        0.312          0.023   0.325

PM~10~, particulate matter with a diameter of less than 10 *μ*m; FeNO, fractional exhaled nitric oxide. *B* is the regression coefficient, and the positive sign of regression coefficient means that the variables are positively associated. The multivariate linear regression analysis is adjusted for age, sex, previous history of respiratory disease (asthma, allergic rhinitis, and chronic obstructive pulmonary disease), pulmonary-related medication before the visit (antihistamine, intranasal corticosteroids, inhaled corticosteroids, and leukotriene receptor antagonist), humidity, and temperature. ^*∗*^Numbers are presented as the average ± standard deviation.

###### 

Correlation analysis of PM~10~ and FeNO by the Pearson correlation and multivariate linear regression analysis according to subgroup.

  Subgroup                                        Number of events   FeNO^*∗*^ (ppb)   PM~10~^*∗*^ ( *μ*g/m^3^)   Univariate   Multivariate            
  ----------------------------------------------- ------------------ ----------------- -------------------------- ------------ -------------- -------- -------
  History of respiratory disease                                                                                                                        
   Asthma^†^                                      367                52.3 ± 43.8       48.0 ± 25.7                0.104        0.047          0.093    0.072
   Allergic rhinitis^†^                           242                44.1 ± 37.0       47.8 ± 24.9                0.091        0.160          0.096    0.128
   Chronic obstructive pulmonary disease^†^       48                 33.9 ± 44.8       47.9 ± 22.7                −0.036       0.807          −0.058   0.708
   No history of respiratory disease^†^           715                23.2 ± 19.8       47.5 ± 25.7                0.081        0.030          0.083    0.024
                                                                                                                                                       
  Pulmonary-related medication before the visit                                                                                                         
   Pulmonary medication^‡^                        309                36.3 ± 29.5       46.7 ± 21.2                −0.05        0.926          0.013    0.814
   No pulmonary medication^‡^                     1265               30.8 ± 31.1       47.5 ± 26.1                0.070        0.012          0.053    0.035

PM~10~, particulate matter with a diameter of less than 10 *μ*m; FeNO, fractional exhaled nitric oxide. *B* is the regression coefficient, and the positive sign of regression coefficient means that the variables are positively associated. PM~10~ values were based on two days before the hospital visit. ^*∗*^Numbers are presented as mean ± standard deviation. ^†^Multivariate linear regression analysis is adjusted for age, sex, pulmonary-related medication before the visit (antihistamine, intranasal corticosteroids, inhaled corticosteroids, and leukotriene receptor antagonist), humidity, and temperature. ^‡^Multivariate linear regression analysis is adjusted for age, sex, previous history of respiratory disease (asthma, allergic rhinitis, and chronic obstructive pulmonary disease), humidity, and temperature.
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